Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

Биовет АД - Тилозин (под формата на фосфат) - премикс за медикаментозен фураж - 100 mg/g - пилета, пуйки, телета

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

Биовет АД - Тилозин (под формата на фосфат) - премикс за медикаментозен фураж - 250 mg/g - пилета, пуйки, телета

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

Биовет АД - tylosine tartarate (еквивалент на тилозина база); Бромгексина хидрохлорид - гранули - 200 mg/g; 8 mg/g - свине

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

boehringer ingelheim vetmedica gmbh - penethamate hydriodide; benethamine пеницилин; сулфат framycetin - интрамамарна суспензия - 100 mg/ 4.5 g; 280 mg/4.5 g; 100 mg/4.5 g - крави

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

huvepharma nv - Тиамулина гидроген фумарат - перорален разтвор - 125 mg/ml - прасета

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

ceva sante animale - Амоксицилин (като Амоксициллина тригидрат) - премикс за медикаментозен фураж - 50 mg/g - прасета

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

Биовет АД - Тилозин тартрат (еквивалент на тилозина база); Бромгексина хидрохлорид - гранули - 333 mg/g; 6.6 mg/g - бройлери, ПСН, пуйки

Bugarska - bugarski - БАБХ (Българска агенция по безопасност на храните)

laboratorios syva, s.a.u. - Энрофлоксацин - разтвор за перорално приложение - 100 mg/ml - бройлери

Europska Unija - bugarski - EMA (European Medicines Agency)

stada arzneimittel ag - бевацизумаб - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Антинеопластични средства - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. За повече информация, както за човешкия рецептор на епидермален фактор за растеж 2 (her2 и) статут, моля, вижте раздел 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. За допълнителна информация относно статуса на her2, моля, вижте раздел 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Europska Unija - bugarski - EMA (European Medicines Agency)

stada arzneimittel ag - ранимизумаб - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Офталмологични - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).